NCT00915967 (POWI) is a NA clinical trial of Vancomycin in Surgical Wound Infections, sponsored by Oregon Health and Science University.

Who is sponsoring NCT00915967?

NCT00915967 is sponsored by Oregon Health and Science University.

What drugs are being tested in NCT00915967?

Interventions in NCT00915967: Vancomycin, Placebo (Saline Solution).

What condition does NCT00915967 study?

NCT00915967 studies Surgical Wound Infections.

Is NCT00915967 still recruiting?

NCT00915967 is currently completed. Last updated 30 April 2019.

Are results published for NCT00915967?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-04-30 · How we verify

NCT00915967: POWI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Neurosurgical Wound Infections

Completed NA Results posted Last updated 30 April 2019

What this trial tests

NA trial testing Vancomycin in Surgical Wound Infections in 214 participants. Completed in 19 December 2014.

Timeline

13 May 2009

Primary endpoint
19 December 2014

19 December 2014

Quick facts

Lead sponsor	Oregon Health and Science University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	214
Start date	13 May 2009
Primary completion	19 December 2014
Estimated completion	19 December 2014
Sites	1 location across United States

Drugs / interventions tested

Vancomycin (vancomycin) — full drug profile →
Placebo (Saline Solution)

Conditions studied

Surgical Wound Infections — all drugs for Surgical Wound Infections →

Sponsor

Oregon Health and Science University

Who can join

Adults 18 to 99, any sex, with Surgical Wound Infections. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Incidence of Infection That Requires Removal of the Neurosurgical Device Primary · Six months post-operation

The primary outcome was infection that required removal of the implanted device within 6 months of surgery. At our institution all patients with evidence of hardware infection have the entire stimulation/pump system removed. Subjects were either seen in clinic or reached by telephone more than 6 months after surgery and assessed for whether they had had infection requiring hardware removal or any superficial infection requiring additional post-operative antibiotics.

Group	Value	95% CI
Vancomycin	97
Saline	98

Adverse events — posted to ClinicalTrials.gov

Time frame: 6 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Vancomycin

Serious: 0/98 (0%)

Deaths: 0/98

Saline

Serious: 0/100 (0%)

Deaths: 0/100

Other adverse events (1 terms — click to expand)

Reaction	System	Vancomycin	Saline
Infection	Surgical and medical procedures	—	—

Data from ClinicalTrials.gov NCT00915967 adverse events section.

Sponsor's own description

The goal of this study is to determine whether injecting the antibiotic vancomycin directly into surgical wounds can decrease the rate of infection following implantation of neurosurgical devices.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vancomycin

Trials testing the same drug.

NCT07435051 — Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cie · Phase 3 · not yet recruiting
NCT06567808 — Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial · Phase 4 · not yet recruiting
NCT06702345 — Clostridioides Difficile Controlled Human Infection Model · NA · not yet recruiting
NCT06716749 — Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty · Phase 2 · completed
NCT06439953 — Irrisept Solution for Instrumented Spine Surgery · NA · recruiting

Other recruiting trials for Surgical Wound Infections

Currently open trials in the same condition.

NCT07189858 — Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada · NA · active not recruiting

Other Oregon Health and Science University trials

Trials by the same sponsor.

NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00915967 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
Last refreshed: 30 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00915967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing